L
6BG
vs
AZT
AZT
Over the past 12 months, 6BG has underperformed AZT, delivering a return of +19% compared to the AZT's +19% growth.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
AZT
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Multiples-Based Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS
F:6BG
|
0.974
EUR
|
|||||
|
Arcticzymes Technologies ASA
OSE:AZT
|
20.2
NOK
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
6BG, AZT
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
L
|
Lytix Biopharma AS
Revenue
|
|||||||||||
|
Arcticzymes Technologies ASA
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
6BG, AZT
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
L
|
Lytix Biopharma AS
F:6BG
|
|||||||||
|
Arcticzymes Technologies ASA
OSE:AZT
|
|||||||||
Compare company's free cash flow with its competitors.
Gross Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS | ||||
|
Arcticzymes Technologies ASA | ||||
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS | ||||
|
Arcticzymes Technologies ASA | ||||
Net Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS | ||||
|
Arcticzymes Technologies ASA | ||||
FCF Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS | ||||
|
Arcticzymes Technologies ASA | ||||
ROIC
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS | ||||
|
Arcticzymes Technologies ASA | ||||
ROCE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS | ||||
|
Arcticzymes Technologies ASA | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
6BG, AZT
Performance Gap
6BG, AZT
Performance By Year
6BG, AZT
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
S
|
Seagen Inc
F:SGT
|